Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Gastrointestinal 1

Conditions

Sarcoma 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Leukemia, Lymphocytic, Chronic, B-Cell 1Colorectal Neoplasms 1Chondrosarcoma 1

Interventions

Docetaxel 2venetoclax 1tanespimycin 1ivosidenib 1birinapant 1belinostat 1Topotecan 1Thiotepa 1Thalidomide 1Surveys and Questionnaires 1Quality of Life 1Pentetic Acid 1Patient Reported Outcome Measures 1Palliative Care 1Nutritional Support 1Molecular Diagnostic Techniques 1Minocycline 1Leucovorin 1Irinotecan 1Immunotherapy 1Imatinib Mesylate 1IFL protocol 1Heparin 1Gemcitabine 1Gelclair 1Fluorouracil 1Filgrastim 1Fentanyl 1Drug Therapy 1Cyproheptadine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Chondrosarcoma × birinapant × Lymphoid × Clear all
NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

IGM Biosciences, Inc.

Phase 1 Terminated
272 enrolled
GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡